Trial Profile

PREDIX HER2 - Neoadjuvant Response-guided Treatment of HER2 Positive Breast Cancer. Part of a Platform of Translational Phase II Trials Based on Molecular Subtypes

Status: Active, no longer recruiting

Phase of Trial: Phase II/III

Latest Information Update: 05 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

01 Apr 2024 Results published in the Breast Cancer Research and Treatment
22 Mar 2024 Results comprising multiomics analysis to predict molecular characteristics of response to neoadjuvant antibody-drug conjugate versus chemotherapy and dual HER2 blockade in HER2 positive breast cancer, presented at the 14th European Breast Cancer Conference
10 Dec 2022 Results evaluating the prognostic and predictive molecular biomarkers during neoadjuvant HER2-targeting therapy, presented at the 45th Annual San Antonio Breast Cancer Symposium

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com